The present invention relates to new improved binder compositions, more specifically curable binder compositions for use in manufacturing products from a collection of non or loosely assembled matter. For example, these binder compositions may be employed to fabricate fiber products which may be made from woven or nonwoven fibers. In one illustrative embodiment, the binder compositions are used to bind glass fibers to make fiberglass. In another illustrative embodiment, the binder compositions are used to bind mineral wool fibers, such as glass wool or stone wool in a matted layer, such as an insulating product. In a further embodiment, the binders are used to make cellulosic compositions. With respect to cellulosic compositions, the binders may be used to bind cellulosic matter to fabricate, for example, wood fiber board or particle board which has desirable physical properties (e.g., mechanical strength). The invention further extends to a product made from loosely assembled matter bound by a binder of the invention.
Several formaldehyde-free binder compositions have been developed in recent times. One such curable binder composition involves sustainable materials and is based on polyester chemistry, more particularly curable aqueous binder compositions comprising a polyacid component or anhydride or salt derivatives thereof, and a polyhydroxy component, possibly together with a silicon containing compound. Another such composition involves the condensation of ammonium salt of inorganic acids or of polycarboxylic acids or an amine, preferably a polyamine, with reducing sugars as thermosets. These chemistries show advantages as compared to prior formaldehyde based technology, but also show certain weaknesses, and there still is a need for improved binder chemistry. Some of the known binder chemistries show a relatively high binder weight loss upon exposure to heat. Some also show undesirable degradation in humid environments which may negatively affect the bond strength properties of the products containing same. There further is an ongoing interest in improving the bond strength of the employed binder compositions, hence providing improved final products, showing improved properties, and/or final products with reduced binder content, at more advantageous costs.
The present invention seeks to provide binders which generate or promote cohesion and are capable of holding a collection of matter together such that the matter adheres in a manner to resist separation. An objective of the present invention is to provide binders showing improved bond strength, as compared to close prior art binder compositions, more particularly such binder compositions based on polyester chemistry or the condensation of ammonium salt of inorganic acid or ammonium salt of polycarboxylic acids or amine with reducing sugars as thermosets.
Another objective of the present invention is to provide cost-effective binder compositions for large volume applications.
Another objective is to provide a binder composition based on renewable and/or sustainable resources.
Further, the invention seeks to provide binder compositions that rapidly cure into strong binders.
Yet another purpose of the invention is to provide an assembly of matter bonded with the invention binder.
The present invention now provides an aqueous curable binder composition comprising the starting materials required for forming a thermoset resin upon curing and a matrix polymer.
The matrix polymer may be of natural and/or synthetic origin. These polymers may act as an active filling agent in the binder formulation, and may form intra- and inter-molecular chain interactions. Naturally derived polymers may advantageously be selected from polysaccharides, such as chitosan, cellulose and its derivatives, such as cellulose ether and ester derivatives. The cellulose ether derivatives can be prepared by carboxymethylation, carboxyethylation and carboxypropylation. Examples of preferred cellulose ether derivatives are: nanocellulose, carboxymethyl cellulose (CMC), sodium carboxymethyl cellulose (NaCMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropylmethyl cellulose (HPMC), methyl cellulose (MC), ethyl cellulose (EC), trityl cellulose, and so on. The preferred cellulose ester derivatives include acetates, butyrates, benzoates, phthalates and anthranilic acid esters of cellulose, preferably, cellulose acetate phthalate (CAP), cellulose acetate butyrate (CAB), cellulose acetate trimelitate (CAT), hydroxylpropylmethyl cellulose phthalate (HPMCP), succinoyl cellulose, cellulose fuoroate, cellulose carbanilate, and mixtures thereof. In some binder compositions cationic cellulose derivatives may be used. Some binder compositions may comprise other polysaccharides such as alginates, starch, chitin and chitosan, agarose, hyaluronic acid, and their derivatives or copolymers (e.g., graft-copolymer, block copolymer, random copolymers), or mixtures thereof.
Chitosan is a polysaccharide derived from crustacean shells, like shrimp shells. Chitosan may have different molecular weights and deacetylation degrees. Preferred are molecular weights between 500 Daltons and 2·106 Daltons, more preferably between 60×103 and 2×105Da.
Synthetically derived polymers may include polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyurethanes, polyesters, polyvinyls and/or their copolymers, aliphatic isocyanate oligomers, azetidinium groups containing polymer (azetidinium polymer) or mixtures thereof.
In one embodiment the binder formulation may comprise polyacrylate, polymethacrylate or polyacrylamide or mixtures thereof, which may be formed from polymerisation of one or more, typically two or three, monomers, which may be present in differing amounts. Preferably the one of the monomers is a substituted alkyl methacrylate or acrylate monomer. The alkyl group of the substituted alkyl function may have from 1 to 10, preferably 1 to 4 carbon atoms and the substituent group may be an alkoxy group with 1 to 4 carbon atoms, such as a methoxy group, or a dialkylamino group, such as dimethylamino. Particularly preferred acrylate monomers are: 2-methoxyacrylate (MEA), 3,5,5-trimethylhexyl acrylate (TMHA), ethylene glycol acrylate (EGA), 2-ethoxyethyl acrylate (EOEA), ethylene glycol diacrylate (EGDA), ethyl 2-ethylacrylate (EEA), (ethyl-cyano)acrylate (ECA), ethyl 2-propyl acrylate (EPA), ethyl 2-(trimethylsilylmethyl)acrylate (ETMSMA), butyl acrylate (BA), butylcyclohexyl acrylate (BCHA), benzyl 2-propyl acrylate (BPA), carboxyethyl acrylate (CEA), 2-(diethylamino)ethyl acrylate (DEAEA), 2-(diethylamino)propyl acrylate (DEAPA). The examples of preferred metharcylate monomers are: methylmethacrylate (MMA), 2-hydroxyethyl methacrylate (HEMA), 2-methoxymethacrylate (MEMA), 2-(diethylamino) ethyl methacrylate (DEAEMA), 2-aminoethyl methacrylate (AEMA), benzyl methacrylate (BMA), 2-butoxyethyl methacrylate (BEMA), 2-(tert-butylamino)ethyl methacrylate (TBAEMA), cyclohexyl methacrylate (CHMA), ethylene glycol methacrylate (EGMA), 2-(diisopropylamino)ethyl methacrylate (DIPAEMA). Preferred acrylamide/methacrylamide monomers are: alkylacrylamide (AAAm), butylacrylamide (BAAm), diethylacrylamide(DEAAm), N,N-dimethyl acrylamide (DMAAm), ethylacrylamide (EAAm), hydroxyethyl acrylamide (HEAAm), hydroxymethyl acrylamide (HMAAm), N-isopropyl acrylamide (NIPAAm), N,N-diethylmethacrylamide (DEMAAm), N-diphenyl methacrylamide (DPMAAm). Preferred polymers comprise two or more monomers and typically a mixture of MEMA or MEA, and DEAEMA or vise versa, in the range between 5:95 and 95:5 percent by weight, advantageously from 10:90 to 90:10, preferably from 20:80 to 80:20, more preferably from 30:70 to 70:30. Optionally further monomers may be present, such as acrylic acid (AA) or methacrylic acid (MAA) in a weight ratio of 1 to 10 percent, preferably about 5 percent by weight. A suitable polymer includes MEMA, DEAEMA and AA in a ratio of 55:40:5 to 75:20:5. Such polymers may comprise one or more monomers which include an aryl group, such as styrene (St) and optionally a dialkylacrylamide group (alkyl representing 1 to 4 carbon atoms), such as dimethylacrylamide (DMAA); and diethylacrylamide (DEAA). Preferably the polymers comprise two monomers selected from styrene and a dialkylacrylamide. Preferred polymers comprise, or consist of the following monomers: St:DMAA and St:DEAA and which may be present in the range of ratios between 40:60 and 95:5. Additional polymers which may be used in binder formulations of the invention may comprise MEA (2-methoxyacrylate) and a dialkylacrylamide group (alkyl representing 1 to 4 carbon atoms), such as dimethylacrylamide (DMAA); and diethylacrylamide (DEAA). Preferred polymers comprise or consist of MEA:DMAA and MEA:DEAA, which may be present in the ratios between 30-80:70-20 respectively.
According to another embodiment of the invention, the binder composition may comprise a polyurethane matrix polymer which provides bond strength and faster curing. Polyurethane polymers may be formed by polymerising a polydiol with a diisocyanate and optionally with an extender molecule, such as a diol. The extender molecules have the effect of modifying the physical character of the polymers, for example, polymer shape, viscosity and polymer state. The polydiol may be selected from the group consisting of but not limited to, poly(polypropylene glycol)-poly(ethylene glycol) (PPG-PEG), polyethylene glycol (PEG), poly(caprolactone)-diol (PCL-diol), poly(lactic acid)-diol (PLA-diol), poly(glycolic acid)-diol (PGA-diol), poly(tetramethylene glycol) (PTMG) also known as poly(butylene glycol), poly[1,6-hexanediol/neopentyl glycol-alt-(adipic acid)]diol (PHNAD), poly[1,6-hexanediol/neopentyl glycol/diethylene glycol-alt-(adipic acid)]diol (PHNDGAD), poly(dimethyl siloxane)-diol (PDMS). The molecular weight of the polydiol may range from Mn=200 to Mn=7000 and it may be present in an amount of 15-55% by weight, such as 20-50% by weight of the polymer. The diisocyanate may be selected from the group consisting of but not limited to methylene diphenyl diisocyanate (MDI), 1,4-phenylene diisocyanate (PDI), 1,1′-methylenebis(4-isocyanatocyclohexane) (HMDI), 2,4-toluene diisocyanate (TDI), hexamethylene diisocyanate (HDI), 1,3-bis(isocynanatomethyl) cyclohexane (BICH). Typically the diisocyanate is present in an amount of 45-55% by weight of the polymer. Suitable extenders include 1,4-butanediol (BD), ethylene glycol (EG), 2,2,3,3,4,4,5,5-octafluoro-1,6-hexanediol (OFHD); and 3-dimethylamino-1,2-propanediol (DMAPD). When present, the extender may be present in an amount of 10-30 mol % of the polymer, typically 10-25%.
In yet another embodiment, the binder composition may comprise polyesters, copolymers or mixtures (blends) thereof. Non limiting examples of preferred polyesters are: polyglycolide or polyglycolic acid (PGA), polylactic acid (PLA), polycaprolactone (PCL), polyhydroxyalkanoate (PHA), polyhydroxybutyrate (PHB), polyethylene adipate (PEA), polybutylene succinate (PBS), poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polytrimethylene terephthalate (PTT), polyethylene naphthalate (PEN), vectran, and/or their copolymers such as PCL-PLA, PCL-PGA, PLA-PGA, PCL-PLA-PCL, PIBVE-b-PCL, and others.
Furthermore, the binder composition of the invention may comprise vinyl polymers and amic acid based polymers, such as poly(pyromellitic dianhydride-co-4,4′oxodianiline) amic acid. Preferably, these may include polyethylene, polypropylene, polybutadiene, polyvinyl chloride (PVC), polyvinyl acetate (PVAc), polyvinyl alcohol (PVA), partially hydrolized polyvinyl acetate, polyacrylonitrile (PAN), polyvinyl butyral (PVB), and polyvinyl toluene (PVT) and/or their copolymers such as PVA-b-PS, PS-b-PMMA, PS-b-PAN, PVA-PGMA, or mixtures thereof. The above said polymers may be incorporated into the binder formulation in homogeneous (aqueous solution) or heterogeneous (emulsion) systems. The solution or emulsion polymers may be present in the composition in an amount ranging from 0.5% up to 50% by weight based on total solids.
In another preferred embodiment, the binder composition may comprise an azetidinium polymer. Such material is known per se and may be obtained by the reaction of a polyamidoamine and a halohydrin. An azetidinium polymer is made up of at least two monomeric units containing a substituted or unsubstituted four membered nitrogen containing heterocycle. The azetidinium polymer may be a homopolymer or a copolymer comprising one or more non-azetidinium monomer units incorporated into the polymer structure. A preferred polyazetidinium suitable for use in accordance with the invention shows the formula
wherein R1 may be C1-C25 alkanediyl, preferably C1-C10 alkanediyl or C1-C5 alkanediyl, possibly substituted with a hydroxyl group, carboxyl functional group or an amine,
Carbohydrate based binders or binder compositions may comprise polymer micro- and/or nano-particles. Preferred micro- and/or nano-particles derived from natural polymers are selected from polysaccharides, such as chitin and chitosan, cellulose and its derivatives, such as cellulose ether and ester derivatives, alginates, starch, agarose, hyaluronic acid, and their derivatives or copolymers, and mixtures thereof. Preferable nano materials are nanocelluloses such as cellulose nanocrystals or cellulose nanowhiskers or nanofibres and/or mixtures thereof.
Synthetically derived polymer micro- and/or nano-particles particularly suitable for carbohydrate based binders are advantageously selected from polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polyurethanes, polyesters, and aliphatic isocyanate oligomers, or copolymers and/or mixtures thereof.
The weight ratio of the matrix polymer may make up from about 1 to 20% dry weight of the binder composition, preferably from about 2 to 18% dry weight, more preferably from 5 to 15% dry weight of the composition.
The said matrix polymers, more specifically the polymers exemplified above, may show a molecular weight ranging from 500 Daltons (Da) to 2×106 Da, preferably from 1×103-5×105 Da, more preferably 5×104 Da-3×105 Da.
One or more pre-formed polymers, or monomers, possibly together with initiator, may be emulsion dispersed or solubilised in the binder composition.
It has been found that by adding additional matrix polymer into the binder composition comprising the starting materials for forming the desired binder resin upon curing, higher bonding strength may be obtained. The addition of such matrix polymer may further reduce the binder loss upon curing of the binder resin. Also, the addition of a matrix polymer reduces the water absorption of the binder, as compared to the same binder which includes no additional matrix polymer.
When a polyester resin type binder is desired, the starting materials are selected from compounds bearing hydroxide functional groups and compounds bearing carboxylic acid functional groups, or anhydride or salt derivatives thereof, such that upon curing under appropriate curing conditions the desired polyester resin is obtained. Such polyester based resins are well known in the technical field. As mentioned above, the hydroxide functional compound may be selected from carbohydrates, such as dextrose, and the compound bearing carboxylic acid functional groups, or anhydride or salt derivatives thereof, may be selected from polycarboxylic acid, anhydride or salt thereof.
The polycarboxylic acid may advantageously be selected from monomeric and polymeric polycarboxylic acids. Illustratively, a monomeric polycarboxylic acid may be a dicarboxylic acid, including, but not limited to, unsaturated aliphatic dicarboxylic acids, saturated aliphatic dicarboxylic acids, aromatic dicarboxylic acids, unsaturated cyclic dicarboxylic acids, saturated cyclic dicarboxylic acids, hydroxy-substituted derivatives thereof, and the like. Or, illustratively, the polycarboxylic acid(s) itself may be a tricarboxylic acid, including, but not limited to, unsaturated aliphatic tricarboxylic acids, saturated aliphatic tricarboxylic acids, aromatic tricarboxylic acids, unsaturated cyclic tricarboxylic acids, saturated cyclic tricarboxylic acids, hydroxy-substituted derivatives thereof, and the like. It is appreciated that any such polycarboxylic acids may be optionally substituted, such as with hydroxy, halo, alkyl, alkoxy, and the like. In one variation, the polycarboxylic acid is the saturated aliphatic tricarboxylic acid, citric acid. Other suitable polycarboxylic acids are contemplated to include, but are not limited to, aconitic acid, adipic acid, azelaic acid, butane tetracarboxylic acid dihydride, butane tricarboxylic acid, chlorendic acid, citraconic acid, dicyclopentadiene-maleic acid adducts, diethylenetriamine pentaacetic acid, adducts of dipentene and maleic acid, ethylenediamine tetraacetic acid (EDTA), fully maleated rosin, maleated tall-oil fatty acids, fumaric acid, glutaric acid, isophthalic acid, itaconic acid, maleated rosin oxidized with potassium peroxide to alcohol then carboxylic acid, maleic acid, malic acid, mesaconic acid, bisphenol A or bisphenol F reacted via the KOLBE-Schmidt reaction with carbon dioxide to introduce 3-4 carboxyl groups, oxalic acid, phthalic acid, sebacic acid, succinic acid, tartaric acid, terephthalic acid, tetrabromophthalic acid, tetrachlorophthalic acid, tetrahydrophthalic acid, trimellitic acid, trimesic acid, and the like, and anhydrides, and combinations thereof. Illustratively, a polymeric polycarboxylic acid may be an acid, for example, polyacrylic acid, polymethacrylic acid, polymaleic acid, and like polymeric polycarboxylic acids, copolymers thereof, anhydrides thereof, and mixtures thereof. Examples of commercially available polyacrylic acids include AQUASET-529 (Rohm & Haas, Philadelphia, Pa., USA), CRITERION 2000 (Kemira, Helsinki, Finland, Europe), NF1 (H. B. Fuller, St. Paul, Minn., USA), and SOKALAN (BASF, Ludwigshafen, Germany, Europe). With respect to SOKALAN, this is a water-soluble polyacrylic copolymer of acrylic acid and maleic acid, having a molecular weight of approximately 4000. AQUASET-529 is a composition containing polyacrylic acid cross-linked with glycerol, also containing sodium hypophosphite as a catalyst. CRITERION 2000 is an acidic solution of a partial salt of polyacrylic acid, having a molecular weight of approximately 2000. With respect to NF1, this is a copolymer containing carboxylic acid functionality and hydroxy functionality, as well as units with neither functionality; NF1 also contains chain transfer agents, such as sodium hypophosphite or organophosphate catalysts.
As described in U.S. Pat. Nos. 5,318,990 and 6,331,350, the polymeric polycarboxylic acid comprises an organic polymer or oligomer containing more than one pendant carboxy group. The polymeric polycarboxylic acid may be a homopolymer or copolymer prepared from unsaturated carboxylic acids including, but not necessarily limited to, acrylic acid, methacrylic acid, crotonic acid, isocrotonic acid, maleic acid, cinnamic acid, 2-methylmaleic acid, itaconic acid, 2-methylitaconic acid, α,β-methyleneglutaric acid, and the like. Alternatively, the polymeric polycarboxylic acid may be prepared from unsaturated anhydrides including, but not necessarily limited to, maleic anhydride, itaconic anhydride, acrylic anhydride, methacrylic anhydride, and the like, as well as mixtures thereof. Methods for polymerizing these acids and anhydrides are well-known in the chemical art. The polymeric polycarboxylic acid may additionally comprise a copolymer of one or more of the aforementioned unsaturated carboxylic acids or anhydrides and one or more vinyl compounds including, but not necessarily limited to, styrene, α-methylstyrene, acrylonitrile, methacrylonitrile, methyl acrylate, ethyl acrylate, n-butyl acrylate, isobutyl acrylate, methyl methacrylate, n-butyl methacrylate, isobutyl methacrylate, glycidyl methacrylate, vinyl methyl ether, vinyl acetate, and the like. Methods for preparing these copolymers are well-known in the art. The polymeric polycarboxylic acids may comprise homopolymers and copolymers of polyacrylic acid. The molecular weight of the polymeric polycarboxylic acid, and in particular polyacrylic acid polymer, may be is less than 10000 Da, less than 5000 Da, or about 3000 Da or less. For example, the molecular weight may be 2000 Da.
The carbohydrate may include one or more reactants having one or more reducing sugars. In one aspect, any carbohydrate reactant should be sufficiently nonvolatile to maximize its ability to remain available for reaction with the amine reactant. The carbohydrate reactant may be a monosaccharide in its aldose or ketose form, including a triose, a tetrose, a pentose, a hexose, or a heptose; or a polysaccharide; or combinations thereof. A carbohydrate reactant may be a reducing sugar, or one that yields one or more reducing sugars in situ under thermal curing conditions. For example, when a triose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, an aldotriose sugar or a ketotriose sugar may be utilized, such as glyceraldehyde and dihydroxyacetone, respectively. When a tetrose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, aldotetrose sugars, such as erythrose and threose; and ketotetrose sugars, such as erythrulose, may be utilized. When a pentose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, aldopentose sugars, such as ribose, arabinose, xylose, and lyxose; and ketopentose sugars, such as ribulose, arabulose, xylulose, and lyxulose, may be utilized. When a hexose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, aldohexose sugars, such as glucose (i.e., dextrose), mannose, galactose, allose, altrose, talose, gulose, and idose; and ketohexose sugars, such as fructose, psicose, sorbose and tagatose, may be utilized. When a heptose serves as the carbohydrate reactant, or is used in combination with other reducing sugars and/or a polysaccharide, a ketoheptose sugar such as sedoheptulose may be utilized. Other stereoisomers of such carbohydrate reactants not known to occur naturally are also contemplated to be useful in preparing the binder compositions as described herein. When a polysaccharide serves as the carbohydrate, or is used in combination with monosaccharides, sucrose, lactose, maltose, starch, and cellulose may be utilized. The carbohydrate component may advantageously comprise oligomers or polymers that result from the hydrolysis of a polysaccharide, such as starch, cellulose or molasses. Such hydrolysates are capable of generating reducing sugars in situ and/or already comprise reducing sugars and further may contribute to the effect of the matrix polymer. Preferred are hydrolysates that show a DE (dextrose equivalent) of 25 to 90, preferably 35 to 85, or 45 to 85, most preferably 55 to 80.
When Maillard compounds based binders are desired, that means binders based on the reaction between a reducing sugar and a nitrogen containing compound, the carbohydrate compound may advantageously be selected from the carbohydrates mentioned here above. Among these dextrose is the most preferred. The nitrogen containing compound may advantageously be selected from ammonium salt of inorganic acids or organic acids and amine compounds.
The inorganic acid part of ammonium salt may advantageously be selected from phosphoric, sulphuric, nitric and carbonic acid. Ammonium sulphate and ammonium phosphate are preferred. The organic acid may be selected from the polycarboxylic acids mentioned here above.
The amine compound may advantageously be selected from polyamine functional compounds comprising primary and/or secondary amine functional groups. In illustrative embodiments, the polyamine is a primary polyamine. In one embodiment, the polyamine may be a molecule having the formula of H2N-Q-NH2, wherein Q is an alkyl, cycloalkyl, heteroalkyl, or cycloheteroalkyl, each of which may be optionally substituted. In one embodiment, Q is an alkyl selected from a group consisting of C2-C24. In another embodiment, Q is an alkyl selected from a group consisting of C2-C8. In another embodiment, Q is an alkyl selected from a group consisting of C3-C7. In yet another embodiment, Q is a C6 alkyl. In one embodiment, Q is selected from the group consisting of a cyclohexyl, cyclopentyl or cyclobutyl. In another embodiment, Q is a benzyl. In illustrative embodiments, the polyamine is selected from a group consisting of a di-amine, tri-amine, tetra-amine, and penta-amine. In one embodiment, the polyamine is a diamine selected from a group consisting of 1,6-diaminohexane and 1,5-diamino-2-methylpentane. In a preferred embodiment, the di-amine is 1,6-diaminohexane. In one embodiment, the polyamine is a tri-amine selected from a group consisting of diethylenetriamine, 1-piperazine-ethaneamine, and bis(hexamethylene)triamine. In another embodiment, the polyamine is a tetra-amine such as triethylenetetramine. In another embodiment, the polyamine is a penta-amine, such as tetraethylenepentamine. In another embodiment, the polyamine is selected from polyethyleneimine (PEI), polyninyl amine, polyether amine, polylysine. As is known to the skilled person, several different types of polyethylenimines are available, such as linear polyethylenimines, branched polyethylenimines and dendrimer type polyethylenimine; all are suitable in the binder compositions of the invention. Similarly, polyetheramines may show a linear form and branched forms, and all are believed to be suitable for the generation of binder compositions and, hence, binders of the invention.
The dry weight ratio of carbohydrate to ammonium salt of inorganic or polycarboxylic acid ranges from about 2 to about 15, preferably from about 2.5 to about 13. The matrix polymer may make up from about 1 to 20% dry weight of the binder composition, preferably from about 2 to 18% dry weight, more preferably from 5 to 15% dry weight of the composition.
The binder compositions of the invention and binders produced therefrom are essentially formaldehyde-free (that is comprising less than about 1 ppm formaldehyde based on the weight of the composition) and do not liberate substantial formaldehyde. They furthermore are based on natural, hence renewable, resources.
The invention compositions may obviously further comprise coupling agents, dyes, antifungal agents, antibacterial agents, hydrophobes and other additives known in the art for such binder applications, as may be appropriate. Silicon-containing coupling agents are typically present in such binders, generally in the range from about 0.1 to about 1% by weight based on the weight of the solids in the binder composition. These additives are obviously selected such as not to antagonise the adhesive properties of the binder nor the mechanical and other desired properties of the final product comprising such binder composition or binder produced therefrom, and advantageously comply with stringent environmental and health related requirements.
Without being bound by theory, it is believed that curing generates highly crosslinked high molecular weight polymers. These may be analysed by techniques generally known in the art, including determination of molecular weight, and other known techniques.
According to the present invention, the term “binder composition” is not particularly restricted and generally includes any composition which is capable of binding loosely assembled matter, either as such or upon curing.
As used herein, the term “aqueous” is not particularly limited and generally relates to a solution and/or dispersion which is based on water as a solvent. Said term further includes compositions or mixtures which contain water and one or more additional solvents. An “aqueous binder composition” of the invention may be a solution or partial solution of one or more of said binder components or may be a dispersion, such as an emulsion or suspension.
The solid content of the invention aqueous binder composition may range from 5 to 95 w %, advantageously from 8 to 90 w %, preferably from 10 to 85 w %, based on the weight of the total aqueous binder composition. More specifically, when used as a binder for mineral wool insulation, the solid content of the aqueous binder composition may be in the range from 5 to 25 w %, preferably from 8 to 20 w %, more preferably from 10 to 20 w % or even 12 to 18 w %, based on the weight of the total aqueous binder composition. When used as a binder in wood boards, the solid content of the aqueous binder composition may range from 50 to 95 w %, preferably 50 to 90 w %, more preferably 55 to 85 w % or even 60 to 80 w %, based upon the weight of the total aqueous binder composition.
Binder compositions of the invention may further comprise nano-particles derived from inorganic materials such as metal-oxides, preferably MgO, CaO, Al2O3 and CaCO4. Furthermore, nanoclays may be incorporated in the binder formulations. Such nanoclays include, without being limited to, montmorillonite, bentonite, kaolinite, hectorite, and halloysite and other organically-modified nanoclays, and/or mixtures thereof. Such inorganic materials may be present in an amount ranging from 0.1 to 10 w %, preferably 0.1 to 5 w %, of solid content of the total composition.
The components of the invention binder compositions may be transported separately and combined shortly before use in the relevant manufacturing plant. It is also possible to transport the binder composition as such.
The binders of the invention may be used to bond a collection of non or loosely assembled matter. The collection of matter includes any collection of matter which comprises fibers selected from mineral fibers, including but not limited to slag wool fibers, stone wool fibers, glass fibers, aramid fibers, ceramic fibers, metal fibers, carbon fibers, polyimide fibers, polyester fibers, rayon fibers, and cellulosic fibers. Further examples of collection of matter include particulates such as coal, sand, cellulosic fibers, wood shavings, saw dust, wood pulp, ground wood, wood chips, wood strands, wood layers, other natural fibers, such as jute, flax, hemp, straw, wood veneers, facings and other particles, woven or non-woven materials. According to a specific embodiment of the invention, the collection of matter is selected from wood particles and mineral fibers.
In one illustrative embodiment, the binder composition of the invention may be used to make insulation products, comprising mineral fibers. In such an application, the fibers are bonded together such that they become organized in a fiberglass mat which may then be processed into an insulation product. In such an application, the fibers are generally present in an amount ranging from 70 to 99%.
According to another embodiment of the invention, the binder may be used to bond cellulosic particles, such as cellulosic fibers, wood shavings, wood pulp and other materials commonly used to manufacture composite wood boards, including fiber boards, particle boards, oriented strand boards etc. Such wood boards show nominal thicknesses ranging from 6 to 30 mm and a modulus of Elasticity of at least about 1000 N/mm2, bending strength of at least about 5 N/mm2 and/or an internal bond strength of at least 0.10 N/mm2. In such applications, the binder content in the final wood board may range from about 5 to 30% wt with respect to the total weight of the wood board notably from 9 to 20%.
According to the invention, the aqueous binder composition may be applied in a manner known per se onto the fiber or particular material. The binder composition may preferably be applied by spray application. Other techniques include roll application or mixing and/or tumbling the collection of matter with the binder composition. As water evaporates the binder composition forms a gel that bonds the particulate material together when arranged into a desirable assembly as detailed further herein below. When curing, the reactive binder components are caused to react to form essentially water insoluble macromolecular binder intermingled with matrix polymer. Curing thus imparts increased adhesion, durability and water resistance as compared to uncured binder. Curing may be effected at temperatures between ambient (from about 10 to 25° C.) and up to 280° C.
According to another aspect, the invention covers a process for the preparation of a bonded assembly of fibrous materials or particulate materials by application of binder, curing and water evaporation. The obtained product may then be further processed in suitable process steps to make intermediate or final products, including but not limited to insulation products. More specifically, a process for the manufacturing of an assembly of fibers or cellulosic particles may comprise the successive or concomitant application of the relevant components of the binder composition described here above or the application of an aqueous binder composition as previously described onto a collection of fibers or particles; the gathering of the coated fibers or particles in an assembly; and curing whereby the carbohydrate and ammonium salt components are caused to react to form a macromolecular binder, and evaporating water.
Curing may be effected at a temperature ranging from 90-200° C., preferably higher than 140° C., more preferably lower than 190° C., typically between 160 and 180° C. In the manufacture of wood boards, curing is performed while the material is subjected to pressing
The invention will be explained in more details in the examples below with reference to the attached Figures, in which:
In the following, examples, the following matrix polymers have been used:
The required amount of matrix polymer was dissolved in water. Similarly, the required amount of dextrose monohydrate (DMH) was dissolved in water separately, followed by addition of ammonium sulphate (AmSO4), diammonium phosphate (DAP) or citric acid monohydrate (CAMH) with constant stirring, as the case may be. Then the desired amount of polymer solution was added to the mixture of DMH solution or vice versa. The mixture was vigorously stirred in order to obtain a homogenous solution, followed by addition of other additives into the solution if applicable and vigorous stirring.
A 50 μL sample of binder solution was dispensed onto a spot of a Whatman™ glass microfiber filter surface. Samples were kept on the top shelf in an oven, avoiding high moisture content inside the oven during curing. For each binder solution, samples were cured for different time periods ranging from 1 minute up to 20 minutes, at different temperatures. After curing, each glass filter sample was cut and fully immersed in 50 mL cold water in a 150 mL glass beaker, and then sonicated for 15 minutes at room temperature. The extract solution was filtered and the absorbance of the extract was determined with a spectrophotometer at 470 nm. The absorbance was plotted as a function of cure time. The results of various binder compositions are presented in
Commercial PF (phenol formaldehyde) impregnated (A4 size) glass fiber veils were placed into a muffle furnace oven for 30 minutes at 600° C. in order to burnout the PF binder, and were then allowed to cool for 30 minutes. The obtained veil samples were weighted.
Approx. 400 g binder solution samples were poured into dip trays, and the obtained veil samples carefully fully immersed into the relevant binder solutions. The impregnated veils were cured at desired temperature for desired periods of time. Binder content was then measured and bond strength determined as follows.
The bond strength of the relevant cured binder impregnated veils was determined by means of a testometric machine (M350-10CT). For each test a cured binder impregnated A4 veil was cut into 8 equal strips. Each strip was tested separately using a 50 Kg load cell (DBBMTCL-50 kg) at an automated test speed of 10 mm/min controlled by winTest Analysis software. Glass veil tensile plates were attached to the testometric machine in order to ensure a 100 mm gap between plates. Samples were placed vertically in the grippers; and the force was tarred to zero. Various parameters such as maximum load at peak, stress at peak and modulus (stiffness) were evaluated by the software, and data presented as an average of 8 samples with standard deviation. The average maximum load at peak or stress at peak defined as the bond strength.
Cured binder impregnated veils were placed in an autoclave (J8341, Vessel: PV02626 with associated safety valve, door interlock and integrated pipework) system. Samples were treated at 90% humidity and at a temperature ranging from 40° C. to 110° C. (full cycle), at a pressure of up to 2.62 bar, for 3 hours. The samples were dried completely in order to ensure no moisture remains onto the veils. The autoclave treated samples were tested for bond strength by means of testometric machine (M350-10CT) described here above, and the results were compared with those of untreated samples.
The evaluation of bond strength was investigated for the veils impregnated with various binder compositions—see
In
The weather stability bond strength of all these DMH/DAP/NaCMC and DMH/DAP/CS compositions was also investigated, and the results are plotted in
Binder solutions were prepared as described above and weighted samples showing a solids content of 2-5% were poured into aluminium petri dishes and kept in an oven for 2 hours at 140° C. The theoretical and experimental values were determined and the weight loss was calculated. The results obtained for various compositions are shown in Table 1 below. As can be seen, the binder weight loss is significantly reduced with addition of matrix polymer in the compositions.
100 g of binder solutions were prepared with desired solid content. Glass microfiber filter GFA were completely immerged and kept for 10 seconds in the relevant binder solutions, and then removed. The binder impregnated GFA samples were cured at desired temperatures, e.g. at 180-190° C. for 10 minutes, and the weight was measured (4 decimal point). Thereafter, the cured GFA samples were fully immerged into a beaker filled with 200 mL water. The samples were maintained for 1 hour under water by means of a glass rod. After 1 hour, the GFA samples were withdrawn and the surface water was absorbed by absorbent paper. The weight of the wet GFA sample was measured. The percentage of water absorption was determined for each sample in three replicates according to the following relationship.
% Water absorption=[(Mass of GFA wet−Mass of GFA dry)/Mass of GFA dry]×100
Table 2 represents water absorption (%) for various compositions of DMH/AmSO4/Polymer, DMH/CAMH/Polymer and DMH/DAP/Polymer, with and without additive (silicone). It can be seen that water absorption is about 247% for standard known DMH/AmSO4 (85/15) binder. With the addition of matrix polymer such as NaCMC and CS the water absorption is significantly reduced, depending on the type and ratio of the matrix polymer used in the formulation. The addition of silicone (1% or 1.5%) in the composition further reduces water absorption significantly.
Binder solutions comprising 2% solids were prepared according to the method disclosed above and showed the compositions indicated in the tables below. Bond strength of weathered and unweathered veils impregnated with the relevant binder compositions and cured for 8 minutes at 200° C. were measured as disclosed above. The results are summarized in the tables below, averaged over 8 replicates.
The data clearly shows the beneficial effect of chitosan polymer matrix (CS) addition to the hydrocarbon based binder compositions.
The experiments were repeated with binder compositions comprising 2% solids. The compositions are shown in the tables below and comprise a polyazetidinium (CA1025) as polymer matrix. Bond strength of weathered and unweathered veils impregnated with the relevant binder compositions and cured for 8 minutes at 200° C. were measured as disclosed above. The results are summarized in Table 6 below, averaged over 8 replicates.
Again, the effect on bond strength of the addition of CA1025 is clearly evidenced.
Accorder to further aspects, the present invention provides an aqueous curable binder composition, an assembly of fibers or particles and a process as set out in the following aspects:
Number | Date | Country | Kind |
---|---|---|---|
1412709 | Jul 2014 | GB | national |
This application is a continuation of U.S. application Ser. No. 17/386,445, filed Jul. 27, 2021, which is a continuation of U.S. application Ser. No. 17/323,991, filed May 18, 2021, which is a continuation of U.S. application Ser. No. 17/194,269, filed Mar. 7, 2021, which is a continuation of U.S. application Ser. No. 17/129,787 (now abandoned), filed Dec. 21, 2020, which is a continuation of U.S. application Ser. No. 17/063,630 (now abandoned), filed Oct. 5, 2020, which is a continuation of U.S. application Ser. No. 16/941,474 (now abandoned), filed Jul. 28, 2020, which is a continuation of U.S. application Ser. No. 15/931,565 (now abandoned), filed May 13, 2020, which is a continuation of U.S. application Ser. No. 15/326,532, filed Jan. 16, 2017, which is a U.S. national counterpart application of International Application Serial No. PCT/EP2015/066455, filed Jul. 17, 2015, under 35 U.S.C. § 371, which claims priority to GB Application Serial No. 1412709.6, filed Jul. 17, 2014, the disclosures of which are hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1801052 | Meigs | Apr 1931 | A |
1801053 | Meigs | Apr 1931 | A |
1886353 | Novotny et al. | Nov 1932 | A |
1902948 | Castle | Mar 1933 | A |
1964263 | Krenke | Jun 1934 | A |
2198874 | Leighton | Apr 1940 | A |
2215825 | Wallace et al. | Sep 1940 | A |
2261295 | Schlack | Nov 1941 | A |
2362086 | Eastes et al. | Nov 1944 | A |
2371990 | Hanford | Mar 1945 | A |
2392105 | Sussman | Jan 1946 | A |
2442989 | Sussman | Jun 1948 | A |
2500665 | Courtright | Mar 1950 | A |
2518956 | Sussman | Aug 1950 | A |
2875073 | Gogek | Feb 1959 | A |
2894920 | Ramos | Jul 1959 | A |
2965504 | Gogek | Dec 1960 | A |
3038462 | Bohdan | Jun 1962 | A |
3138473 | Floyd et al. | Jun 1964 | A |
3222243 | Gaston et al. | Dec 1965 | A |
3231349 | Stalego | Jan 1966 | A |
3232821 | Banks et al. | Feb 1966 | A |
3297419 | Eyre, Jr. | Jan 1967 | A |
3513001 | Woodhead et al. | May 1970 | A |
3551365 | Matalon | Dec 1970 | A |
3554788 | Fechillas | Jan 1971 | A |
3784408 | Jaffe et al. | Jan 1974 | A |
3791807 | Etzel et al. | Feb 1974 | A |
3802897 | Voigt | Apr 1974 | A |
3809664 | Burr | May 1974 | A |
3826767 | Hoover et al. | Jul 1974 | A |
3856606 | Fan et al. | Dec 1974 | A |
3867119 | Takeo et al. | Feb 1975 | A |
3907724 | Higginbottom | Sep 1975 | A |
3911048 | Nistri et al. | Oct 1975 | A |
3919134 | Higginbottom | Nov 1975 | A |
3922466 | Bell et al. | Nov 1975 | A |
3955031 | Jones et al. | May 1976 | A |
3956204 | Higginbottom | May 1976 | A |
3961081 | McKenzie | Jun 1976 | A |
3971807 | Brack | Jul 1976 | A |
4014726 | Fargo | Mar 1977 | A |
4028290 | Reid | Jun 1977 | A |
4048127 | Gibbons et al. | Sep 1977 | A |
4054713 | Sakaguchi et al. | Oct 1977 | A |
4085076 | Gibbons et al. | Apr 1978 | A |
4097427 | Aitken et al. | Jun 1978 | A |
4107379 | Stofko | Aug 1978 | A |
4109057 | Nakamura et al. | Aug 1978 | A |
4144027 | Habib | Mar 1979 | A |
4148765 | Nelson | Apr 1979 | A |
4183997 | Stofko | Jan 1980 | A |
4184986 | Krasnobajew et al. | Jan 1980 | A |
4186053 | Krasnobajew et al. | Jan 1980 | A |
4201247 | Shannon | May 1980 | A |
4201857 | Krasnobajew et al. | May 1980 | A |
4217414 | Walon | Aug 1980 | A |
4233432 | Curtis, Jr. | Nov 1980 | A |
4246367 | Curtis, Jr. | Jan 1981 | A |
4259190 | Fahey | Mar 1981 | A |
4265963 | Matalon | May 1981 | A |
4278573 | Tessler | Jul 1981 | A |
4296173 | Fahey | Oct 1981 | A |
4301310 | Wagner | Nov 1981 | A |
4310585 | Shannon | Jan 1982 | A |
4322523 | Wagner | Mar 1982 | A |
4330443 | Rankin | May 1982 | A |
4333484 | Keritsis | Jun 1982 | A |
4357194 | Stofko | Nov 1982 | A |
4361588 | Herz | Nov 1982 | A |
4379101 | Smith | Apr 1983 | A |
4393019 | Geimer | Jul 1983 | A |
4396430 | Matalon | Aug 1983 | A |
4400496 | Butler et al. | Aug 1983 | A |
4464523 | Neigel et al. | Aug 1984 | A |
4506684 | Keritsis | Mar 1985 | A |
4520143 | Jellinek | May 1985 | A |
4524164 | Viswanathan et al. | Jun 1985 | A |
4631226 | Jellinek | Dec 1986 | A |
4654259 | Stofko | Mar 1987 | A |
4668716 | Pepe et al. | May 1987 | A |
4692478 | Viswanathan et al. | Sep 1987 | A |
4714727 | Hume, III | Dec 1987 | A |
4720295 | Bronshtein | Jan 1988 | A |
4734996 | Kim et al. | Apr 1988 | A |
4754056 | Ansel et al. | Jun 1988 | A |
4761184 | Markessini | Aug 1988 | A |
4780339 | Lacourse et al. | Oct 1988 | A |
4828643 | Newman et al. | May 1989 | A |
4845162 | Schmitt et al. | Jul 1989 | A |
4906237 | Johansson | Mar 1990 | A |
4912147 | Pfoehler et al. | Mar 1990 | A |
4918861 | Carpenter et al. | Apr 1990 | A |
4923980 | Blomberg | May 1990 | A |
4950444 | Deboufie et al. | Aug 1990 | A |
4988780 | Das et al. | Jan 1991 | A |
4992519 | Mukherjee | Feb 1991 | A |
5001202 | Denis et al. | Mar 1991 | A |
5013405 | Izard | May 1991 | A |
5032431 | Conner et al. | Jul 1991 | A |
5037930 | Shih | Aug 1991 | A |
5041595 | Yang et al. | Aug 1991 | A |
5089342 | Dhein et al. | Feb 1992 | A |
5095054 | Lay et al. | Mar 1992 | A |
5106615 | Dikstein | Apr 1992 | A |
5114004 | Isono et al. | May 1992 | A |
5123949 | Thiessen | Jun 1992 | A |
5124369 | Vandichel et al. | Jun 1992 | A |
5128407 | Layton et al. | Jul 1992 | A |
5143582 | Arkens et al. | Sep 1992 | A |
5151465 | Le-Khac | Sep 1992 | A |
5167738 | Bichot et al. | Dec 1992 | A |
5198492 | Stack | Mar 1993 | A |
5217741 | Kawachi et al. | Jun 1993 | A |
5218048 | Abe et al. | Jun 1993 | A |
5240498 | Matalon et al. | Aug 1993 | A |
5244474 | Lorcks et al. | Sep 1993 | A |
5278222 | Stack | Jan 1994 | A |
5300144 | Adams | Apr 1994 | A |
5300192 | Hansen et al. | Apr 1994 | A |
5308896 | Hansen et al. | May 1994 | A |
5318990 | Strauss | Jun 1994 | A |
5336753 | Jung et al. | Aug 1994 | A |
5336755 | Pape | Aug 1994 | A |
5336766 | Koga et al. | Aug 1994 | A |
5340868 | Strauss et al. | Aug 1994 | A |
5346541 | Goldman | Sep 1994 | A |
5352480 | Hansen et al. | Oct 1994 | A |
5367849 | Bullock | Nov 1994 | A |
5371194 | Ferretti | Dec 1994 | A |
5387665 | Misawa et al. | Feb 1995 | A |
5389716 | Graves | Feb 1995 | A |
5393849 | Srinivasan et al. | Feb 1995 | A |
5416139 | Zeiszler | May 1995 | A |
5421838 | Gosset et al. | Jun 1995 | A |
5424418 | Duflot | Jun 1995 | A |
5434233 | Kiely et al. | Jul 1995 | A |
5447977 | Hansen et al. | Sep 1995 | A |
5470843 | Stahl et al. | Nov 1995 | A |
5480973 | Goodlad et al. | Jan 1996 | A |
5492756 | Seale et al. | Feb 1996 | A |
5498662 | Tanaka et al. | Mar 1996 | A |
5503920 | Alkire et al. | Apr 1996 | A |
5534612 | Taylor et al. | Jul 1996 | A |
5536766 | Seyffer et al. | Jul 1996 | A |
5538783 | Hansen et al. | Jul 1996 | A |
5543215 | Hansen et al. | Aug 1996 | A |
5545279 | Hall et al. | Aug 1996 | A |
5547541 | Hansen et al. | Aug 1996 | A |
5547745 | Hansen et al. | Aug 1996 | A |
5550189 | Qin et al. | Aug 1996 | A |
5554730 | Woiszwillo et al. | Sep 1996 | A |
5562740 | Cook et al. | Oct 1996 | A |
5571618 | Hansen et al. | Nov 1996 | A |
5578678 | Hartmann et al. | Nov 1996 | A |
5580856 | Prestrelski et al. | Dec 1996 | A |
5582682 | Ferretti | Dec 1996 | A |
5583193 | Aravindakshan et al. | Dec 1996 | A |
5589256 | Hansen et al. | Dec 1996 | A |
5589536 | Golino et al. | Dec 1996 | A |
5607759 | Hansen et al. | Mar 1997 | A |
5608011 | Eck et al. | Mar 1997 | A |
5609727 | Hansen et al. | Mar 1997 | A |
5614570 | Hansen et al. | Mar 1997 | A |
5620940 | Birbara et al. | Apr 1997 | A |
5621026 | Tanaka et al. | Apr 1997 | A |
5633298 | Arfaei et al. | May 1997 | A |
5641561 | Hansen et al. | Jun 1997 | A |
5643978 | Darwin et al. | Jul 1997 | A |
5645756 | Dubin et al. | Jul 1997 | A |
5660904 | Andersen et al. | Aug 1997 | A |
5661213 | Arkens et al. | Aug 1997 | A |
5670585 | Taylor et al. | Sep 1997 | A |
5672418 | Hansen et al. | Sep 1997 | A |
5672659 | Shalaby et al. | Sep 1997 | A |
5690715 | Schiwek | Nov 1997 | A |
5691060 | Levy | Nov 1997 | A |
5693411 | Hansen et al. | Dec 1997 | A |
5719092 | Arrington | Feb 1998 | A |
5719228 | Taylor et al. | Feb 1998 | A |
5733624 | Syme et al. | Mar 1998 | A |
5756580 | Natori et al. | May 1998 | A |
5763524 | Arkens et al. | Jun 1998 | A |
5788243 | Harshaw et al. | Aug 1998 | A |
5788423 | Perkins | Aug 1998 | A |
5807364 | Hansen | Sep 1998 | A |
5855987 | Margel et al. | Jan 1999 | A |
5863985 | Shalaby et al. | Jan 1999 | A |
5885337 | Nohr et al. | Mar 1999 | A |
5895804 | Lee et al. | Apr 1999 | A |
5905115 | Luitjes et al. | May 1999 | A |
5916503 | Rettenbacher | Jun 1999 | A |
5919528 | Huijs et al. | Jul 1999 | A |
5919831 | Philipp | Jul 1999 | A |
5922403 | Tecle | Jul 1999 | A |
5925722 | Exner et al. | Jul 1999 | A |
5929184 | Holmes-Farley et al. | Jul 1999 | A |
5929196 | Kissel et al. | Jul 1999 | A |
5932344 | Ikemoto et al. | Aug 1999 | A |
5932665 | DePorter et al. | Aug 1999 | A |
5932689 | Arkens et al. | Aug 1999 | A |
5942123 | McArdle | Aug 1999 | A |
5954869 | Elfersy et al. | Sep 1999 | A |
5977224 | Cheung et al. | Nov 1999 | A |
5977232 | Arkens et al. | Nov 1999 | A |
5981719 | Woiszwillo et al. | Nov 1999 | A |
5983586 | Berdan, II et al. | Nov 1999 | A |
5990216 | Cai et al. | Nov 1999 | A |
5993709 | Bonomo et al. | Nov 1999 | A |
6022615 | Rettenbacher | Feb 2000 | A |
6067821 | Jackson et al. | May 2000 | A |
6071549 | Hansen | Jun 2000 | A |
6071994 | Hummerich et al. | Jun 2000 | A |
6072086 | James et al. | Jun 2000 | A |
6077883 | Taylor et al. | Jun 2000 | A |
6090925 | Woiszwillo et al. | Jul 2000 | A |
6114033 | Ikemoto et al. | Sep 2000 | A |
6114464 | Reck et al. | Sep 2000 | A |
6133347 | Vickers, Jr. et al. | Oct 2000 | A |
6136916 | Arkens et al. | Oct 2000 | A |
6139619 | Zaretskiy et al. | Oct 2000 | A |
6143243 | Gershun et al. | Nov 2000 | A |
6171444 | Nigam | Jan 2001 | B1 |
6171654 | Salsman et al. | Jan 2001 | B1 |
6180037 | Anderson et al. | Jan 2001 | B1 |
6194512 | Chen et al. | Feb 2001 | B1 |
6210472 | Kwan et al. | Apr 2001 | B1 |
6221958 | Shalaby et al. | Apr 2001 | B1 |
6221973 | Arkens et al. | Apr 2001 | B1 |
6231721 | Quick et al. | May 2001 | B1 |
6274661 | Chen et al. | Aug 2001 | B1 |
6281298 | Papsin, Jr. | Aug 2001 | B1 |
6299677 | Johnson et al. | Oct 2001 | B1 |
6299936 | Reck et al. | Oct 2001 | B1 |
6307732 | Tsubaki et al. | Oct 2001 | B1 |
6310227 | Sarama et al. | Oct 2001 | B1 |
6313102 | Colaco et al. | Nov 2001 | B1 |
6319683 | James et al. | Nov 2001 | B1 |
6331350 | Taylor et al. | Dec 2001 | B1 |
6331513 | Zaid et al. | Dec 2001 | B1 |
6340411 | Hansen et al. | Jan 2002 | B1 |
6348530 | Reck et al. | Feb 2002 | B1 |
6365079 | Winkler et al. | Apr 2002 | B1 |
6372077 | Tecle | Apr 2002 | B1 |
6379739 | Formanek et al. | Apr 2002 | B1 |
6379814 | Dupre et al. | Apr 2002 | B1 |
6395856 | Petty et al. | May 2002 | B1 |
6403665 | Sieker et al. | Jun 2002 | B1 |
6407225 | Mang et al. | Jun 2002 | B1 |
6410036 | De Rosa et al. | Jun 2002 | B1 |
6440204 | Rogols et al. | Aug 2002 | B1 |
6441122 | DeMott et al. | Aug 2002 | B1 |
6461553 | Hansen et al. | Oct 2002 | B1 |
6468442 | Bytnar | Oct 2002 | B2 |
6468730 | Fujiwara et al. | Oct 2002 | B2 |
6469120 | Elfersy et al. | Oct 2002 | B1 |
6475552 | Shah et al. | Nov 2002 | B1 |
6482875 | Lorenz et al. | Nov 2002 | B2 |
6482876 | Witt-Nuesslein et al. | Nov 2002 | B1 |
6495656 | Haile et al. | Dec 2002 | B1 |
6521339 | Hansen et al. | Feb 2003 | B1 |
6525009 | Sachdev et al. | Feb 2003 | B2 |
6538057 | Wildburg et al. | Mar 2003 | B1 |
6547867 | Rogols et al. | Apr 2003 | B2 |
6555616 | Helbing et al. | Apr 2003 | B1 |
6559302 | Shah et al. | May 2003 | B1 |
6562267 | Hansen et al. | May 2003 | B1 |
6596103 | Hansen et al. | Jul 2003 | B1 |
6613378 | Erhan et al. | Sep 2003 | B1 |
6638882 | Helbing et al. | Oct 2003 | B1 |
6638884 | Quick et al. | Oct 2003 | B2 |
6699945 | Chen et al. | Mar 2004 | B1 |
6706853 | Stanssens et al. | Mar 2004 | B1 |
6719862 | Quick et al. | Apr 2004 | B2 |
6730730 | Hansen et al. | May 2004 | B1 |
6753361 | Kroner et al. | Jun 2004 | B2 |
6818694 | Hindi et al. | Nov 2004 | B2 |
6821547 | Shah et al. | Nov 2004 | B2 |
6852247 | Bytnar | Feb 2005 | B2 |
6858074 | Anderson et al. | Feb 2005 | B2 |
6861495 | Barsotti et al. | Mar 2005 | B2 |
6864044 | Ishikawa et al. | Mar 2005 | B2 |
6878800 | Husemoen et al. | Apr 2005 | B2 |
6884849 | Chen et al. | Apr 2005 | B2 |
6955844 | Tagge et al. | Oct 2005 | B2 |
6962714 | Hei et al. | Nov 2005 | B2 |
6989171 | Portman | Jan 2006 | B2 |
6992203 | Trusovs | Jan 2006 | B2 |
7018490 | Hansen et al. | Mar 2006 | B2 |
7026390 | O'Brien-Bernini | Apr 2006 | B2 |
7029717 | Ojima et al. | Apr 2006 | B1 |
7067579 | Taylor et al. | Jun 2006 | B2 |
7083831 | Koch et al. | Aug 2006 | B1 |
7090745 | Beckman et al. | Aug 2006 | B2 |
7141626 | Rodrigues et al. | Nov 2006 | B2 |
7144474 | Hansen et al. | Dec 2006 | B1 |
7195792 | Boston et al. | Mar 2007 | B2 |
7201778 | Smith et al. | Apr 2007 | B2 |
7201825 | Dezutter et al. | Apr 2007 | B2 |
7202326 | Kuroda et al. | Apr 2007 | B2 |
7241487 | Taylor et al. | Jul 2007 | B2 |
7458235 | Beaufils et al. | Dec 2008 | B2 |
7514027 | Horres et al. | Apr 2009 | B2 |
7655711 | Swift et al. | Feb 2010 | B2 |
7772347 | Swift et al. | Aug 2010 | B2 |
7795354 | Srinivasan et al. | Sep 2010 | B2 |
7803879 | Srinivasan et al. | Sep 2010 | B2 |
7807771 | Swift et al. | Oct 2010 | B2 |
7842382 | Helbing | Nov 2010 | B2 |
7854980 | Jackson et al. | Dec 2010 | B2 |
7883693 | Sehl et al. | Feb 2011 | B2 |
7888445 | Swift et al. | Feb 2011 | B2 |
7947765 | Swift et al. | May 2011 | B2 |
8114210 | Hampson et al. | Feb 2012 | B2 |
8182648 | Swift et al. | May 2012 | B2 |
8211923 | Wagner et al. | Jul 2012 | B2 |
8232334 | Kelly | Jul 2012 | B2 |
8372900 | Shooshtari et al. | Feb 2013 | B2 |
8377564 | Shooshtari et al. | Feb 2013 | B2 |
8501838 | Jackson et al. | Aug 2013 | B2 |
8680224 | Zhang et al. | Mar 2014 | B2 |
8691934 | Helbing et al. | Apr 2014 | B2 |
8900495 | Pacorel et al. | Dec 2014 | B2 |
9394431 | Alavi | Jul 2016 | B2 |
10208414 | Lester et al. | Feb 2019 | B2 |
20010017427 | Rosthauser et al. | Aug 2001 | A1 |
20010046824 | Nigam | Nov 2001 | A1 |
20020000100 | Burg et al. | Jan 2002 | A1 |
20020025435 | Hansen et al. | Feb 2002 | A1 |
20020026025 | Kuo et al. | Feb 2002 | A1 |
20020028857 | Holy | Mar 2002 | A1 |
20020032253 | Lorenz et al. | Mar 2002 | A1 |
20020042473 | Trollsas et al. | Apr 2002 | A1 |
20020091185 | Taylor et al. | Jul 2002 | A1 |
20020096278 | Foster et al. | Jul 2002 | A1 |
20020123598 | Sieker et al. | Sep 2002 | A1 |
20020130439 | Kroner et al. | Sep 2002 | A1 |
20020161108 | Schultz et al. | Oct 2002 | A1 |
20020197352 | Portman | Dec 2002 | A1 |
20030005857 | Minami et al. | Jan 2003 | A1 |
20030040239 | Toas et al. | Feb 2003 | A1 |
20030044513 | Shah et al. | Mar 2003 | A1 |
20030066523 | Lewis et al. | Apr 2003 | A1 |
20030071879 | Swenson | Apr 2003 | A1 |
20030116294 | Kehrer et al. | Jun 2003 | A1 |
20030134945 | Capps | Jul 2003 | A1 |
20030148084 | Trocino | Aug 2003 | A1 |
20030153690 | Husemoen et al. | Aug 2003 | A1 |
20030185991 | Wigger et al. | Oct 2003 | A1 |
20030203117 | Bartkowiak et al. | Oct 2003 | A1 |
20040002567 | Chen et al. | Jan 2004 | A1 |
20040019168 | Soerens et al. | Jan 2004 | A1 |
20040024170 | Husemoen et al. | Feb 2004 | A1 |
20040033269 | Hei et al. | Feb 2004 | A1 |
20040033747 | Miller et al. | Feb 2004 | A1 |
20040034154 | Tutin et al. | Feb 2004 | A1 |
20040038017 | Tutin et al. | Feb 2004 | A1 |
20040048531 | Belmares et al. | Mar 2004 | A1 |
20040077055 | Fosdick et al. | Apr 2004 | A1 |
20040079499 | Dezutter et al. | Apr 2004 | A1 |
20040087024 | Bellocq et al. | May 2004 | A1 |
20040087719 | Rautschek et al. | May 2004 | A1 |
20040122166 | O'Brien-Bernini et al. | Jun 2004 | A1 |
20040131874 | Tutin et al. | Jul 2004 | A1 |
20040144706 | Beaufils et al. | Jul 2004 | A1 |
20040152824 | Dobrowolski | Aug 2004 | A1 |
20040161993 | Tripp et al. | Aug 2004 | A1 |
20040209851 | Nelson et al. | Oct 2004 | A1 |
20040213930 | Halabisky | Oct 2004 | A1 |
20040220368 | Li et al. | Nov 2004 | A1 |
20040249066 | Heinzman et al. | Dec 2004 | A1 |
20040254285 | Rodrigues et al. | Dec 2004 | A1 |
20040260082 | Van Der Wilden et al. | Dec 2004 | A1 |
20050001198 | Bytnar | Jan 2005 | A1 |
20050017394 | Hochsmann et al. | Jan 2005 | A1 |
20050027283 | Richard et al. | Feb 2005 | A1 |
20050033037 | Trusovs | Feb 2005 | A1 |
20050048212 | Clamen et al. | Mar 2005 | A1 |
20050059770 | Srinivasan et al. | Mar 2005 | A1 |
20050171085 | Pinto et al. | Aug 2005 | A1 |
20050196421 | Hunter et al. | Sep 2005 | A1 |
20050202224 | Helbing | Sep 2005 | A1 |
20050208852 | Weber | Sep 2005 | A1 |
20050215153 | Cossement et al. | Sep 2005 | A1 |
20050245669 | Clungeon et al. | Nov 2005 | A1 |
20050275133 | Cabell et al. | Dec 2005 | A1 |
20050288479 | Kuroda et al. | Dec 2005 | A1 |
20060005580 | Espiard et al. | Jan 2006 | A1 |
20060009569 | Charbonneau et al. | Jan 2006 | A1 |
20060044302 | Chen | Mar 2006 | A1 |
20060099870 | Garcia et al. | May 2006 | A1 |
20060111480 | Hansen et al. | May 2006 | A1 |
20060124538 | Morcrette et al. | Jun 2006 | A1 |
20060135433 | Murray et al. | Jun 2006 | A1 |
20060141177 | Ligtenberg et al. | Jun 2006 | A1 |
20060179892 | Horres et al. | Aug 2006 | A1 |
20060188465 | Perrier et al. | Aug 2006 | A1 |
20060198954 | Frechem et al. | Sep 2006 | A1 |
20060231487 | Bartley et al. | Oct 2006 | A1 |
20060252855 | Pisanova et al. | Nov 2006 | A1 |
20060281622 | Maricourt et al. | Dec 2006 | A1 |
20070006390 | Clamen et al. | Jan 2007 | A1 |
20070009582 | Madsen et al. | Jan 2007 | A1 |
20070027281 | Michl et al. | Feb 2007 | A1 |
20070039520 | Crews et al. | Feb 2007 | A1 |
20070082983 | Crews et al. | Apr 2007 | A1 |
20070123679 | Swift et al. | May 2007 | A1 |
20070123680 | Swift et al. | May 2007 | A1 |
20070129522 | Burckhardt et al. | Jun 2007 | A1 |
20070142596 | Swift et al. | Jun 2007 | A1 |
20070158022 | Heep et al. | Jul 2007 | A1 |
20070184740 | Keller et al. | Aug 2007 | A1 |
20070191574 | Miller et al. | Aug 2007 | A1 |
20070270070 | Othman | Nov 2007 | A1 |
20070287018 | Tutin et al. | Dec 2007 | A1 |
20070292618 | Srinivasan et al. | Dec 2007 | A1 |
20070292619 | Srinivasan et al. | Dec 2007 | A1 |
20070298274 | Eriksson et al. | Dec 2007 | A1 |
20080009209 | Clamen et al. | Jan 2008 | A1 |
20080009616 | Frank et al. | Jan 2008 | A1 |
20080051539 | Kelly | Feb 2008 | A1 |
20080060551 | Crews et al. | Mar 2008 | A1 |
20080081138 | Moore et al. | Apr 2008 | A1 |
20080108741 | Van Herwijnen et al. | May 2008 | A1 |
20080160260 | Wada et al. | Jul 2008 | A1 |
20080160302 | Asrar et al. | Jul 2008 | A1 |
20080194738 | Crews et al. | Aug 2008 | A1 |
20090169867 | Kelly | Jul 2009 | A1 |
20090170978 | Kelly | Jul 2009 | A1 |
20090227732 | Glockner et al. | Sep 2009 | A1 |
20090275699 | Zhang et al. | Nov 2009 | A1 |
20090301972 | Hines et al. | Dec 2009 | A1 |
20090304919 | Huenig et al. | Dec 2009 | A1 |
20090306255 | Patel et al. | Dec 2009 | A1 |
20090324915 | Swift et al. | Dec 2009 | A1 |
20100029160 | Srinivasan et al. | Feb 2010 | A1 |
20100058661 | Jackson et al. | Mar 2010 | A1 |
20100080976 | Jackson et al. | Apr 2010 | A1 |
20100084598 | Jackson et al. | Apr 2010 | A1 |
20100086726 | Jackson et al. | Apr 2010 | A1 |
20100087571 | Jackson et al. | Apr 2010 | A1 |
20100098947 | Inoue et al. | Apr 2010 | A1 |
20100117023 | Dopico et al. | May 2010 | A1 |
20100129593 | Rempt et al. | May 2010 | A1 |
20100129640 | Kelly | May 2010 | A1 |
20100130649 | Swift et al. | May 2010 | A1 |
20100175826 | Huenig et al. | Jul 2010 | A1 |
20100210595 | Wagner et al. | Aug 2010 | A1 |
20100222463 | Brady et al. | Sep 2010 | A1 |
20100222566 | Fosdick et al. | Sep 2010 | A1 |
20100282996 | Jaffrennou et al. | Nov 2010 | A1 |
20100301256 | Hampson et al. | Dec 2010 | A1 |
20100320113 | Swift | Dec 2010 | A1 |
20110021672 | Crews et al. | Jan 2011 | A1 |
20110039111 | Shooshtari | Feb 2011 | A1 |
20110040010 | Shooshtari | Feb 2011 | A1 |
20110042303 | Shooshtari et al. | Feb 2011 | A1 |
20110045966 | Shooshtari et al. | Feb 2011 | A1 |
20110089074 | Jackson et al. | Apr 2011 | A1 |
20110135937 | Swift et al. | Jun 2011 | A1 |
20110190425 | Swift | Aug 2011 | A1 |
20110220835 | Swift et al. | Sep 2011 | A1 |
20110223364 | Hawkins | Sep 2011 | A1 |
20110256790 | Toas et al. | Oct 2011 | A1 |
20110260094 | Hampson et al. | Oct 2011 | A1 |
20110262648 | Lee et al. | Oct 2011 | A1 |
20110263757 | Rand et al. | Oct 2011 | A1 |
20110306726 | Bailey et al. | Dec 2011 | A1 |
20120133073 | Pacorel et al. | May 2012 | A1 |
20120135152 | Finch | May 2012 | A1 |
20120156954 | Eckert et al. | Jun 2012 | A1 |
20130029150 | Appley et al. | Jan 2013 | A1 |
20130032749 | Jaffrennou et al. | Feb 2013 | A1 |
20130047888 | Mueller et al. | Feb 2013 | A1 |
20130059075 | Appley et al. | Mar 2013 | A1 |
20130082205 | Mueller et al. | Apr 2013 | A1 |
20130174758 | Mueller | Jul 2013 | A1 |
20130234362 | Swift et al. | Sep 2013 | A1 |
20130236650 | Swift et al. | Sep 2013 | A1 |
20130237113 | Swift et al. | Sep 2013 | A1 |
20130244524 | Swift et al. | Sep 2013 | A1 |
20130323492 | Finch et al. | Dec 2013 | A1 |
20140083328 | Lochel, Jr. | Mar 2014 | A1 |
20140091247 | Jackson et al. | Apr 2014 | A1 |
20140134909 | Guo et al. | May 2014 | A1 |
20140357787 | Jobber et al. | Dec 2014 | A1 |
Number | Date | Country |
---|---|---|
8538765 | Aug 1985 | AU |
9640921 | Jul 1997 | AU |
1090026 | Nov 1980 | CA |
2037214 | Sep 1991 | CA |
2232334 | Nov 1998 | CA |
2458333 | Dec 1999 | CA |
2278946 | Jan 2000 | CA |
2470783 | Dec 2004 | CA |
1251738 | May 2000 | CN |
1905054 | Aug 1969 | DE |
4142261 | Jun 1993 | DE |
4233622 | Apr 1994 | DE |
4308089 | Sep 1994 | DE |
102004033561 | Sep 2005 | DE |
102005023431 | Nov 2006 | DE |
0044614 | Jan 1982 | EP |
0099801 | Feb 1984 | EP |
354023 | Feb 1990 | EP |
0375235 | Jun 1990 | EP |
0461995 | Dec 1991 | EP |
0524518 | Jan 1993 | EP |
0547819 | Jun 1993 | EP |
0583086 | Feb 1994 | EP |
0714754 | Jun 1996 | EP |
796681 | Sep 1997 | EP |
0826710 | Mar 1998 | EP |
856494 | Aug 1998 | EP |
0873976 | Oct 1998 | EP |
878135 | Nov 1998 | EP |
0882756 | Dec 1998 | EP |
0911361 | Apr 1999 | EP |
915811 | May 1999 | EP |
936060 | Aug 1999 | EP |
976866 | Feb 2000 | EP |
0990729 | Apr 2000 | EP |
1038433 | Sep 2000 | EP |
1193288 | Apr 2002 | EP |
1084167 | Sep 2002 | EP |
1268702 | Jan 2003 | EP |
1382642 | Jan 2004 | EP |
1486547 | Dec 2004 | EP |
1522642 | Apr 2005 | EP |
1698598 | Sep 2006 | EP |
1767566 | Apr 2007 | EP |
2223941 | Sep 2010 | EP |
2253663 | Nov 2010 | EP |
2669349 | Dec 2013 | EP |
2679624 | Jan 2014 | EP |
2692810 | Feb 2014 | EP |
3221412 | Sep 2017 | EP |
2614388 | Oct 1988 | FR |
770561 | Mar 1957 | GB |
809675 | Mar 1959 | GB |
926749 | May 1963 | GB |
1391172 | Apr 1975 | GB |
1469331 | Apr 1977 | GB |
1512066 | May 1978 | GB |
1525541 | Sep 1978 | GB |
2047258 | Nov 1980 | GB |
2078805 | Jan 1982 | GB |
2173523 | Oct 1986 | GB |
2251438 | Jul 1992 | GB |
53113784 | Oct 1978 | JP |
57101100 | Jun 1982 | JP |
58011193 | Jan 1983 | JP |
61195647 | Aug 1986 | JP |
3-173680 | Jul 1991 | JP |
05186635 | Jul 1993 | JP |
7-034023 | Feb 1995 | JP |
09157627 | Jun 1997 | JP |
10234314 | Sep 1998 | JP |
11035491 | Feb 1999 | JP |
11181690 | Jul 1999 | JP |
2000327841 | Nov 2000 | JP |
2002293576 | Oct 2002 | JP |
2003147276 | May 2003 | JP |
2003238921 | Aug 2003 | JP |
2004060058 | Feb 2004 | JP |
2005306919 | Nov 2005 | JP |
549563 | Jan 2008 | NZ |
1765996 | Aug 1995 | RU |
374400 | Mar 1973 | SU |
1990007541 | Jul 1990 | WO |
1992012198 | Jul 1992 | WO |
1995034517 | Dec 1995 | WO |
1997049646 | Dec 1997 | WO |
1999036368 | Jul 1999 | WO |
199947765 | Sep 1999 | WO |
199960042 | Nov 1999 | WO |
199960043 | Nov 1999 | WO |
200058085 | Oct 2000 | WO |
2001014491 | Mar 2001 | WO |
2001059026 | Aug 2001 | WO |
200200429 | Jan 2002 | WO |
200206178 | Jan 2002 | WO |
2003029496 | Apr 2003 | WO |
2003071879 | Sep 2003 | WO |
2003106561 | Dec 2003 | WO |
2004007615 | Jan 2004 | WO |
2004061038 | Jul 2004 | WO |
2004076734 | Sep 2004 | WO |
2005061647 | Jul 2005 | WO |
2005087837 | Sep 2005 | WO |
2006044302 | Apr 2006 | WO |
2006136614 | Dec 2006 | WO |
2007014236 | Feb 2007 | WO |
2007024020 | Mar 2007 | WO |
2007050964 | May 2007 | WO |
2007112335 | Oct 2007 | WO |
2008089851 | Jul 2008 | WO |
WO-2008089847 | Jul 2008 | WO |
2008141201 | Nov 2008 | WO |
2009019235 | Feb 2009 | WO |
2009079254 | Jun 2009 | WO |
2009129084 | Oct 2009 | WO |
2010027937 | Mar 2010 | WO |
2010106181 | Sep 2010 | WO |
2010139899 | Dec 2010 | WO |
2011019590 | Feb 2011 | WO |
2011019593 | Feb 2011 | WO |
2011019597 | Feb 2011 | WO |
2011019598 | Feb 2011 | WO |
2011022224 | Feb 2011 | WO |
2011022226 | Feb 2011 | WO |
2011022227 | Feb 2011 | WO |
2011042610 | Apr 2011 | WO |
2011044490 | Apr 2011 | WO |
2011138459 | Nov 2011 | WO |
2011150203 | Dec 2011 | WO |
2012172265 | Dec 2012 | WO |
2013021112 | Feb 2013 | WO |
2013036752 | Mar 2013 | WO |
2013150123 | Oct 2013 | WO |
2014001518 | Jan 2014 | WO |
Entry |
---|
Nov. 16, Office action for co-pending U.S. Appl. No. 15/326,532 (9 pages)—Nov. 16, 2018. |
Office action for co-pending U.S. Appl. No. 15/326,532 (11 pages)—Mar. 14, 2019. |
Office action for co-pending U.S. Appl. No. 15/326,532 (9 pages)—Aug. 6, 2019. |
Office action for co-pending U.S. Appl. No. 15/326,532 (8 pages)—Dec. 17, 2019. |
International Search Report and Written Opinion for PCT/EP2015/066455, completed Oct. 26, 2015. |
Office action for co-pending U.S. Appl. No. 12/667,718 (5 pages)—Sep. 3, 2013. |
Office action for co-pending U.S. Appl. No. 12/667,718 (6 pages)—Sep. 9, 2014. |
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—Oct. 7, 2011. |
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—May 10, 2012. |
Office action for co-pending U.S. Appl. No. 12/671,922 (9 pages)—Sep. 23, 2014. |
Office action for co-pending U.S. Appl. No. 12/671,922 (5 pages)—Apr. 4, 2016. |
Office action for co-pending U.S. Appl. No. 13/388,408 (5 pages)—Aug. 15, 2013. |
Office action for co-pending U.S. Appl. No. 13/371,829 (9 pages)—Dec. 20, 2012. |
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—Jul. 12, 2013. |
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—Aug. 12, 2014. |
Office action for co-pending U.S. Appl. No. 13/637,794 (8 pages)—Aug. 12, 2013. |
Office action for co-pending U.S. Appl. No. 13/637,794 (9 pages)—Mar. 26, 2014. |
Office action for co-pending U.S. Appl. No. 13/696,439 (11 pages)—Jan. 8, 2014. |
Office action for co-pending U.S. Appl. No. 13/696,452 (7 pages)—Jan. 13, 2015. |
Office action for co-pending U.S. Appl. No. 13/696,452 (9 pages)—Oct. 27, 2015. |
Office action for co-pending U.S. Appl. No. 13/702,144 (6 pages)—Jan. 10, 2014. |
Office action for co-pending U.S. Appl. No. 13/702,144 (7 pages)—Jul. 29, 2014. |
Office action for co-pending U.S. Appl. No. 13/823,818 (9 pages)—Mar. 26, 2015. |
Office action for co-pending U.S. Appl. No. 13/866,368 (16 pages)—Aug. 29, 2013. |
Office action for co-pending U.S. Appl. No. 13/866,368 (11 pages)—Apr. 16, 2014. |
Office action for co-pending U.S. Appl. No. 13/866,368 (8 pages)—Aug. 21, 2014. |
Office action for co-pending U.S. Appl. No. 13/866,419 (14 pages)—Sep. 20, 2013. |
Office action for co-pending U.S. Appl. No. 13/866,419 (10 pages)—Apr. 25, 2014. |
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—Oct. 9, 2014. |
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—Sep. 25, 2015. |
Office action for co-pending U.S. Appl. No. 13/868,233 (23 pages)—Aug. 13, 2013. |
Office action for co-pending U.S. Appl. No. 13/868,233 (12 pages)—Apr. 15, 2014. |
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—Oct. 7, 2014. |
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—Jul. 16, 2015. |
Office action for co-pending U.S. Appl. No. 13/868,238 (8 pages)—Jul. 16, 2014. |
Office action for co-pending U.S. Appl. No. 12/976,379 (7 pages)—Jan. 10, 2012. |
Office action for co-pending U.S. Appl. No. 12/976,379 (6 pages)—Jul. 27, 2012. |
Office action for co-pending U.S. Appl. No. 12/976,379 (9 pages)—Mar. 7, 2013. |
Office action for co-pending U.S. Appl. No. 12/976,379 (8 pages)—Aug. 20, 2013. |
Office action for co-pending U.S. Appl. No. 12/599,858 (8 pages)—May 11, 2011. |
Office action for co-pending U.S. Appl. No. 13/341,542 (8 pages)—Dec. 26, 2012. |
Office action for co-pending U.S. Appl. No. 13/341,542 (7 pages)—Feb. 10, 2014. |
Office action for co-pending U.S. Appl. No. 14/026,394 (6 pages)—Aug. 14, 2014. |
Office action for co-pending U.S. Appl. No. 14/272,556 (14 pages)—Nov. 20, 2014. |
Office action for co-pending U.S. Appl. No. 14/272,556 (12 pages)—Sep. 17, 2015. |
Office action for co-pending U.S. Appl. No. 14/342,069 (17 pages)—Dec. 29, 2015. |
Office action for co-pending U.S. Appl. No. 14/342,069 (22 pages)—Sep. 2, 2016. |
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—Sep. 26, 2017. |
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—Jun. 6, 2018. |
Office action for co-pending U.S. Appl. No. 14/390,445 (14 pages)—Dec. 3, 2015. |
Office action for co-pending U.S. Appl. No. 14/649,277 (9 pages)—Jul. 22, 2016. |
Office action for co-pending U.S. Appl. No. 14/686,915 (8 pages)—Nov. 18, 2016. |
Office action for co-pending U.S. Appl. No. 14/810,765 (7 pages)—Jan. 29, 2016. |
Office action for co-pending U.S. Appl. No. 14/828,916 (8 pages)—Nov. 25, 2016. |
Office action for co-pending U.S. Appl. No. 14/867,502 (9 pages)—Nov. 18, 2016. |
International Search Report and Written Opinion for PCT/US2008/059730, completed Sep. 22, 2008. |
International Search Report and Written Opinion for PCT/US2008/069046, completed Sep. 25, 2008. |
International Search Report and Written Opinion for PCT/EP2011/059317, completed Jul. 15, 2011. |
International Search Report for PCT/EP2008/060185, completed Oct. 23, 2008. |
International Search Report for PCT/EP2011/057363, completed Sep. 5, 2011. |
Ames, J.M., “The Maillard Browning Reaction—an Update,” Chemistry & Industry, No. 17, 1988, 4 pages. |
“Gamma-aminopropyltrimethoxysilane,” Hawley's Condensed Chemical Dictionary, 14th Edition, John Wiley & Sons, Inc., 2002, 1 page. |
Hodge, J.E., Chemistry of Browning Reactions in Model Systems, 1953, J. Agric. Food Chem., vol. 1, No. 15, pp. 928-943. |
Agyei-Aye et al., “The Role of Anion in the Reaction of Reducing Sugars with Ammonium Salts,” Carbohydrate Research 2002, 337: 2273-2277. |
Laroque et al., “Kinetic study on the Maillard reaction. Consideration of sugar reactivity,” Food Chemistry 2008, 111: 1032-1042. |
Bjorksten et al., “Polyester Resin—Glass Fiber Laminates,” Industrial and Engineering Chemistry (1954). |
Dow Corning, “A Guide to Silane Solutions,” 2005. |
Knauf Data Sheet, 2006. |
Molasses Corporation, United States Sugar Corporation, http://www.suga-lik.com/molasses/composition.html (Sep. 29, 2003). |
Clamen, Guy, “Acrylic Thermosets: A Safe Alternative to Formaldehyde Resins,” Nonwovens World, Apr.-May 2004, pp. 96-102. |
Opposition to AU 2006272595, Amended Statement of Grounds and Particulars, issued from Australian Patent Office, Jul. 6, 2012, 22 pages. |
Decision re Opposition to AU 2006272595, issued from Australian Patent Office, Aug. 14, 2015, 25 pages. |
Opposition to EP 1732968, Notice of Opposition: Prior Art, Scope of the Patent, Reasons for the Opposition, issued from European Patent Office, Mar. 8, 2012, 18 pages. |
Decision re Opposition to EP 1732968, issued from the European Patent Office, Nov. 14, 2014, 5 pages. |
Opposition to EA 019802, submitted to Eurasian Patent Office on Dec. 26, 2014, 36 pages. |
Decision re Opposition to EA 019802, issued by Eurasian Patent Office on Aug. 18, 2015, 15 pages. |
Owens Corning Retiree Update: What Goes Around, Comes Around: A tale of Natural Binders, revised Mar. 20, 2013, p. 4. |
A.P. Bryant, “The Terminology of Sugars,” Industrial and Engineering Chemistry, vol. 26, No. 2, p. 231, Feb. 1934. |
Food Flavor Chemistry, p. 162, Mar. 21, 2009 (English Abstract). |
Mswanathan, T., “Chapter 28: Thermosetting Adhesive Resins from Whey and Whey Byproducts,” in Adhesives from Renewable Resources, ACS Symposium Series, Hemingway, R.W., et al. (Eds.), American Chemical Society, Washington, DC (1989). |
Mswanathan, T., and Richardson, T., “Thermosetting Adhesive Resins from Whey and Whey Byproducts,” Ind. Eng. Chem. Prod. Res. Dev. 23:644-47, American Chemical Society, United States (1984). |
Residential Energy Conservation: vol. 1, Congress of the U.S., Office of Technology Assessment (Ed.), 357 pages (Jan. 1, 1979). |
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—Sep. 21, 2012. |
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—Apr. 4, 2013. |
Office action for co-pending U.S. Appl. No. 12/524,512 (7 pages)—Aug. 6, 2012. |
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—Apr. 1, 2013. |
Office action for co-pending U.S. Appl. No. 12/524,512 (14 pages)—Nov. 12, 2014. |
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—Jul. 10, 2015. |
Office action for co-pending U.S. Appl. No. 12/524,512 (10 pages)—Mar. 23, 2016. |
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—Oct. 5, 2016. |
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—Apr. 6, 2018. |
Office action for co-pending U.S. Appl. No. 12/524,512 (15 pages)—Jan. 17, 2019. |
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—Jun. 7, 2012. |
Office action for co-pending U.S. Appl. No. 12/524,469 (8 pages)—Jan. 29, 2013. |
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—Aug. 20, 2013. |
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—Jun. 9, 2014. |
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—Oct. 17, 2014. |
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—Jul. 23, 2015. |
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—Jun. 21, 2012. |
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—Jun. 6, 2013. |
Office action for co-pending U.S. Appl. No. 12/524,539 (12 pages)—Dec. 17, 2014. |
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—Jul. 15, 2015. |
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—Mar. 23, 2016. |
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—Dec. 29, 2016. |
Office action for co-pending U.S. Appl. No. 12/524,522 (4 pages)—Oct. 11, 2011. |
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (16 pages)—Jan. 4, 2016. |
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (19 pages)—Jan. 4, 2016. |
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (14 pages)—Jan. 4, 2016. |
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,926,464 (29 pages)—Oct. 2, 2018. |
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,464,207 (28 pages)—Oct. 2, 2018. |
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,469,747 (29 pages)—Oct. 3, 2018. |
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,828,287 (22 pages)—Oct. 16, 2018. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (13 pages)—Jul. 17, 2020. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (14 pages)—Jul. 31, 2020. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (18 pages)—Aug. 5, 2020. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (17 pages)—Oct. 16, 2020. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (16 pages)—Oct. 16, 2020. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (16 pages)—Nov. 9, 2020. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (19 pages)—Aug. 27, 2021. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,464,207 (14 pages)—Sep. 9, 2022. |
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,464,207 (9 pages)—Jun. 8, 2023. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (16 pages)—Sep. 7, 2021. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,926,464 (15 pages)—Mar. 21, 2023. |
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,926,464 (6 pages)—Jul. 25, 2023. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (10 pages)—Sep. 16, 2021. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,469,747 (9 pages)—Feb. 28, 2023. |
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,469,747 (6 pages)—Jul. 25, 2023. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (13 pages)—Dec. 1, 2021. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 8,114,210 (11 pages)—Mar. 27, 2023. |
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 8,114,210 (6 pages)—Aug. 8, 2023. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (13 pages)—Jan. 28, 2022. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 8,940,089 (11 pages)—Jul. 17, 2023. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (11 pages)—Feb. 1, 2022. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,828,287 (9 pages)—Feb. 28, 2023. |
Notice of Intent to Issue Ex Parte Re-examination Certificate re U.S. Pat. No. 9,828,287 (6 pages)—Jul. 25, 2023. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (13 pages)—Feb. 1, 2022. |
Office Action in Ex Parte Reexamination of U.S. Pat. No. 9,039,827 (11 pages)—Aug. 16, 2023. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 8,114,210 (4 pages)—May 27, 2021. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,464,207 (4 pages)—Apr. 19, 2021. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,828,287 (5 pages)—May 5, 2021. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,926,464 (5 pages)—May 5, 2021. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,469,747 (8 pages)—May 21, 2021. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,039,827 (3 pages)—Jul. 2, 2021. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 8,940,089 (4 pages)—Jul. 13, 2021. |
Petition for Post Grant Review of U.S. Pat. No. 10,968,629 (50 pages, filed Jan. 6, 2022 by Petitioner Rockwool International A/S). |
Denial of Petition for Post Grant Review of U.S. Pat. No. 10,968,629 entered by Patent Trial and Appeal Board (19 pages)—Jul. 6, 2022. |
Statement of Revocation Grounds re GB2496951—Claimant Rockwool International (May 21, 2018, 22 pages). |
Statement of Revocation Grounds re GB2451719—Claimant Rockwool International (May 18, 2018, 22 pages). |
Expert Report re Revocation of GB2451719 and GB2496951—Claimant Rockwool International (Nov. 12, 2018, 11 pages). |
United Kingdom Intellectual Property Office, Decision in Rockwool International v. Knauf Insulation Limited, Application under Section 72 for revocation of patents GB2451719 and GB2496951 (May 28, 2019—18 pages). |
Gogek Attorney Comments re U.S. Pat. No. 2,965,504—Apr. 6, 1960 (3 pages). |
Gogek Affidavit Under Rule 132 re U.S. Pat. No. 2,965,504—Feb. 26, 1960 (3 pages). |
Office action for co-pending U.S. Appl. No. 15/172,432 (16 pages)—Apr. 17, 2017. |
Office action for co-pending U.S. Appl. No. 15/702,087 (5 pages)—Nov. 9, 2018. |
Office action for co-pending U.S. Appl. No. 15/177,442 (17 pages)—May 19, 2017. |
Office action for co-pending U.S. Appl. No. 15/378,159 (18 pages)—Mar. 2, 2017. |
Office action for co-pending U.S. Appl. No. 15/222,122 (8 pages)—Nov. 20, 2017. |
Office action for co-pending U.S. Appl. No. 15/310,837 (13 pages)—Jun. 21, 2018. |
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—Mar. 28, 2017. |
Office action for co-pending U.S. Appl. No. 15/411,972 (8 pages)—Nov. 29, 2017. |
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—Jun. 14, 2018. |
Office action for co-pending U.S. Appl. No. 15/116,254 (8 pages)—Apr. 26, 2018. |
Office action for co-pending U.S. Appl. No. 15/116,254 (10 pages)—Aug. 15, 2018. |
Office action for co-pending U.S. Appl. No. 15/116,254 (12 pages)—Nov. 3, 2021. |
Office action for co-pending U.S. Appl. No. 15/333,670 (5 pages)—Dec. 8, 2017. |
Office Action for co-pending U.S. Appl. No. 14/116,048 (10 pages)—Jun. 23, 2017. |
Office action for co-pending U.S. Appl. No. 15/959,131 (8 pages)—Nov. 8, 2019. |
Office action for co-pending U.S. Appl. No. 15/822,102 (6 pages)—Dec. 6, 2019. |
Office action for co-pending U.S. Appl. No. 15/690,623 (7 pages)—May 24, 2019. |
Office action for co-pending U.S. Appl. No. 15/690,623 (6 pages)—Jan. 9, 2020. |
Office action for co-pending U.S. Appl. No. 16/357,320 (7 pages)—Jun. 10, 2021. |
Office action for co-pending U.S. Appl. No. 16/357,320 (9 pages)—Dec. 29, 2021. |
Office action for co-pending U.S. Appl. No. 16/357,320 (9 pages)—Apr. 14, 2022. |
Other Information—Narrative of verbal disclosure of Brian Swift (1 page)—May 13, 2014. |
Petition for Inter Partes Review of U.S. Pat. No. 8,114,210 (52 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,114,210 (58 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with Petition for Inter Partes Review of U.S. Pat. No. 8,114,210). |
1st Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (68 pages, filed Jun. 19, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
2nd Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (62 pages, filed Nov. 2, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (33 pages)—Jan. 12, 2016. |
Decision2 of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (27 pages)—May 9, 2016. |
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. D. 631,670 based on 1st Petition (56 pages)—Jan. 11, 2017. |
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. D. 631,670 based on 2nd Petition (55 pages)—May 8, 2017. |
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decisions in Inter Partes Reviews of U.S. Pat. No. D. 631,670 (2 pages)—Jul. 13, 2018. |
1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (61 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (70 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089). |
2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (56 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (67 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089). |
3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (62 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (76 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089). |
Declaration of Dr. Elam Leed (11 pages, filed July 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively). |
Declaration of Dr. Jonathan Vickers (10 pages, filed July 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively). |
1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (60 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (72 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827). |
2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (51 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (65 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827). |
3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (57 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (75 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827). |
Declaration of Dr. Elam Leed (11 pages, filed Jul. 29, August 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively). |
Declaration of Dr. Jonathan Vickers (10 pages, filed Jul. 29, Aug. 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively). |
Petition for Inter Partes Review of U.S. Pat. No. 9,469,747 (67 pages, filed Mar. 20, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Petition for Inter Partes Review of U.S. Pat. No. 9,828,287 (86 pages, filed Mar. 23, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Petition for Inter Partes Review of U.S. Pat. No. 9,464,207 (78 pages, filed Mar. 28, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Petition for Inter Partes Review of U.S. Pat. No. 9,926,464 (74 pages, filed Mar. 30, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.). |
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,888,445, mailed Dec. 24, 2013, in Control No. 90/013,029, 11 pages. |
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,772,347, mailed Dec. 24, 2013, in Control No. 90/013,030, 14 pages. |
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,854,980, mailed Apr. 15, 2014, in Control No. 90/013,156, 20 pages. |
Declaration of Jan Rud Andersen submitted in Ex parte Reexamination Control No. 90/013,030, as Document OTH-C, Oct. 10, 2013, 4 pages. |
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (20 pages)—Jul. 24, 2015. |
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (23 pages)—Jul. 24, 2015. |
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (31 pages)—Aug. 18, 2015. |
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (4 pages)—Oct. 6, 2015. |
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (4 pages)—Oct. 6, 2015. |
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (4 pages)—Nov. 18, 2015. |
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (8 pages)—Mar. 23, 2016. |
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (8 pages)—Mar. 23, 2016. |
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (8 pages)—Mar. 22, 2016. |
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (17 pages)—Sep. 29, 2016. |
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (18 pages)—Sep. 29, 2016. |
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (22 pages)—Sep. 30, 2016. |
Court of Appeals for Federal Circuit Judgment from Consolidated Appeal of PTAB Decisions in Ex Parte Reexamination of U.S. Pat. Nos. 7,888,445, 7,772,347 and 7,854,980 (5 pages)—Mar. 9, 2018. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,772,347 (4 pages)—Oct. 24, 2018. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,888,445 (4 pages)—Dec. 7, 2018. |
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,888,445 (14 pages)—Sep. 24, 2020. |
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,772,347 (13 pages)—Sep. 25, 2020. |
Decision of USPTO to Reopen Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (7 pages)—Jan. 7, 2019. |
Non-final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (26 pages)—Apr. 3, 2019. |
Final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (11 pages)—Aug. 8, 2019. |
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,854,980 (3 pages)—Oct. 29, 2019. |
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,807,771 (4 pages)—Jan. 30, 2014. |
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,854,980 (6 pages)—Aug. 31, 2017. |
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (34 pages)—May 1, 2015. |
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (36 pages)—May 1, 2015. |
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (25 pages)—Jul. 30, 2015. |
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (5 pages)—Dec. 9, 2015. |
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (5 pages)—Dec. 9, 2015. |
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (22 pages)—Oct. 17, 2016 |
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (17 pages)—Oct. 17, 2016. |
Court of Appeals for Federal Circuit Opinion/Judgment from Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (13 pages)—Feb. 27, 2017. |
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (25 pages)—Sep. 8, 2017. |
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (24 pages)—Sep. 8, 2017. |
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (7 pages)—Feb. 12, 2018. |
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (7 pages)—Feb. 12, 2018. |
Court of Appeals for Federal Circuit Decision re Consolidated Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 and U.S. Pat. No. 7,888,445 (14 pages)—Oct. 15, 2019. |
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (3 pages)—Jul. 1, 2020. |
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (3 pages)—Jul. 1, 2020. |
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. 8,114,210 (20 pages)—Oct. 21, 2015. |
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. 8,114,210 (39 pages)—Oct. 19, 2016. |
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decision in Inter Partes Review of U.S. Pat. No. 8,114,210 (5 pages)—Jan. 16, 2018. |
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (11 pages)—Apr. 9, 2020. |
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (16 pages)—Dec. 17, 2015. |
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (19 pages)—Dec. 17, 2015. |
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (14 pages)—Dec. 17, 2015. |
U.S. Pat. No. 2,965,504—Part 1 (10 pages)—Dec. 20, 1960. |
U.S. Pat. No. 2,965,504—Part 2 (14 pages)—Dec. 20, 1960. |
U.S. Pat. No. 2,965,504—Part 3 (14 pages)—Dec. 20, 1960. |
Number | Date | Country | |
---|---|---|---|
20220098452 A1 | Mar 2022 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17386445 | Jul 2021 | US |
Child | 17498146 | US | |
Parent | 17323991 | May 2021 | US |
Child | 17386445 | US | |
Parent | 17194269 | Mar 2021 | US |
Child | 17323991 | US | |
Parent | 17129787 | Dec 2020 | US |
Child | 17194269 | US | |
Parent | 17063630 | Oct 2020 | US |
Child | 17129787 | US | |
Parent | 16941474 | Jul 2020 | US |
Child | 17063630 | US | |
Parent | 15931565 | May 2020 | US |
Child | 16941474 | US | |
Parent | 15326532 | US | |
Child | 15931565 | US |